首页> 外文期刊>Risk Management and Healthcare Policy >MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease
【24h】

MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease

机译:MAFLD标准指导脂肪肝病患者的亚型

获取原文
       

摘要

Background and Aims:Metabolic associated fatty liver disease (MAFLD) is diagnosed in patients with hepatic steatosis when they have the following three metabolic conditions: obesity/overweight, diabetes and metabolic dysregulation, either alone or in combination. There is no clarity whether subtypes of MAFLD diagnosed by different metabolic conditions carry different levels of risk for intra- and extra-hepatic organs. This study aims to depict the characteristics of these subtypes in a large population.Methods:The data were retrieved from the third National Health and Nutrition Examination Surveys of the United States. The clinical and biochemical features in different MAFLD subtypes were compared. The outcome of interest was significant and advanced fibrosis.Results:Out of 4,087 (31.24%) participants with MAFLD, 1,165 (28.51%) were diagnosed by single metabolic condition, 2,053 (50.23%) by two conditions, and 869 (21.26%) by all three metabolic conditions. With increasing numbers of metabolic conditions, participants tended to be older, were more likely to be female, and had more severe renal impairment and liver fibrosis (P0.05). MAFLD patients with a lower number of metabolic conditions were more likely to have excessive alcohol consumption. Among MAFLD with single metabolic condition, those diagnosed by diabetes alone had the highest proportion of advanced fibrosis identified by non-invasive fibrosis models (P0.05).Conclusion:More metabolic conditions upon the diagnosis of MALFD indicate higher risk of fibrosis. Patients with MAFLD diagnosed by diabetes alone are more likely to have advanced hepatic fibrosis than those with other metabolic conditions alone. Individualized management is required for MAFLD with different subtypes.? 2021 Huang et al.
机译:背景和目的:代谢相关的脂肪肝疾病(MAFLD)被诊断为肝脏脂肪变性的患者,当它们具有以下三种代谢条件:肥胖/超重,糖尿病和代谢的多重剂单独或组合。无明确的是不同代谢病症诊断的MAFLD亚型是否携带不同肝癌和肝脏器官的风险水平。本研究旨在描绘在大人物中的这些亚型的特征。方法:从美国的第三次全国健康和营养检查调查中取消了数据。比较了不同MAFD亚型的临床和生化特征。兴趣的结果是显着和先进的纤维化。结果:4,087(31.24%)的MAFLD参与者,1,165(28.51%)被单一代谢病症诊断,2,053(50.23%)两种条件,869例(21.26%)通过所有三种代谢条件。随着代谢条件的越来越多,参与者倾向于老化,更有可能是女性,并且具有更严重的肾损伤和肝纤维化(P <0.05)。较少代谢条件较少的MAFLD患者更有可能具有过量的饮酒。单独的糖尿病患者单独诊断的那些通过非侵入性纤维化模型(P <0.05)鉴定的先进纤维化比例最高(P <0.05)。结论:MALFD诊断后的更多代谢条件表明纤维化的风险较高。单独被糖尿病诊断患有MAFLD的患者更可能具有高级肝纤维化,而不是单独具有其他代谢条件的肝纤维化。使用不同亚型的MAFD需要个性化管理。 2021 Huang等人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号